Charles River Laboratories International (NYSE:CRL) Given New $387.00 Price Target at UBS Group

Key Points

• UBS raised its price target on Charles River Laboratories to $387 from $357 and reiterated a Buy rating, implying 23.82% upside from the stock’s cited price.
• Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus and average target of $308.17, with 13 Buy, three Hold, and one Sell rating.
• Charles River beat quarterly earnings and revenue estimates, reporting $3.09 per share and $982.7 million in revenue; however, revenue was down 2.2% year over year, and shares fell on the day described.

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its price target lifted by analysts at UBS Group from $357.00 to $387.00 in a report issued on Thursday, Benzinga reports. The firm currently has a "buy" rating on the medical research company's stock. UBS Group's price target indicates a potential upside of 23.82% from the stock's current price.

A number of other equities research analysts also recently commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Charles River Laboratories International in a report on Monday, September 28th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. TD Cowen increased their price target on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, September 25th. Morgan Stanley increased their price target on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the company an "overweight" rating in a report on Monday, October 12th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the company a "buy" rating in a research note on Friday, September 25th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Moderate Buy" and an average target price of $308.17.

Charles River Laboratories International Stock Performance

NYSE CRL traded down $13.75 on Thursday, hitting $312.54. 1,661,444 shares of the company's stock were exchanged, compared to its average volume of 966,386. The firm has a market cap of $14.92 billion, a price-to-earnings ratio of -64.44, a P/E/G ratio of 3.29 and a beta of 1.36. The firm's 50-day moving average price is $304.55 and its two-hundred day moving average price is $224.12. Charles River Laboratories International has a fifty-two week low of $146.20 and a fifty-two week high of $379.63. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, beating the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The business had revenue of $982.73 million during the quarter, compared to analysts' expectations of $960.36 million. During the same period last year, the firm earned $2.43 EPS. The company's quarterly revenue was down 2.2% compared to the same quarter last year. On average, research analysts expect that Charles River Laboratories International will post 11.38 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director James Foster sold 33,561 shares of the company's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the sale, the director owned 31,596 shares of the company's stock, valued at approximately $9,478,800. This represents a 51.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 3,714 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.66, for a total value of $1,038,657.24. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company's stock, valued at approximately $1,344,325.62. This represents a 43.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 102,299 shares of company stock valued at $31,050,863. Company insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Amundi grew its stake in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock valued at $285,001,000 after acquiring an additional 210,260 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Charles River Laboratories International by 230.9% during the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock worth $59,044,000 after acquiring an additional 142,716 shares during the last quarter. Retirement Systems of Alabama raised its position in Charles River Laboratories International by 1,246.1% during the third quarter. Retirement Systems of Alabama now owns 136,211 shares of the medical research company's stock worth $40,184,000 after acquiring an additional 126,092 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its position in Charles River Laboratories International by 2,268.2% during the third quarter. State of Alaska Department of Revenue now owns 111,781 shares of the medical research company's stock worth $32,977,000 after acquiring an additional 107,061 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International News Roundup

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River reported Q3 adjusted earnings of $3.09 per share and revenue of $982.7 million, topping analyst estimates. Margin expansion helped earnings, and the company raised its 2026 outlook. Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
• Positive Sentiment: Barclays raised its price target to $375 and maintained an Overweight rating; RBC lifted its target to $352 and kept an Outperform rating. The higher targets signal continued analyst optimism. Barclays stock recommendations Royal Bank of Canada stock recommendations
• Neutral Sentiment: The market’s reaction appears cautious despite the earnings beat: revenue exceeded estimates but was down 2.2% from a year earlier, and coverage noted the shares fell despite the beat and raised outlook. CRL Q3 2026 deep dive
• Negative Sentiment: Zacks Research downgraded CRL from Strong Buy to Hold, adding a more cautious analyst view. Zacks Research stock recommendations

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.